727 related articles for article (PubMed ID: 19509067)
41. Rapamycin inhibits human in stent restenosis vascular smooth muscle cells independently of pRB phosphorylation and p53.
Rosner D; McCarthy N; Bennett M
Cardiovasc Res; 2005 Jun; 66(3):601-10. PubMed ID: 15914125
[TBL] [Abstract][Full Text] [Related]
42. Expression and mechanism of mammalian target of rapamycin in age-related renal cell senescence and organ aging.
Zhuo L; Cai G; Liu F; Fu B; Liu W; Hong Q; Ma Q; Peng Y; Wang J; Chen X
Mech Ageing Dev; 2009 Oct; 130(10):700-8. PubMed ID: 19698731
[TBL] [Abstract][Full Text] [Related]
43. Pharmacodynamic Evaluation of CCI-779, an Inhibitor of mTOR, in Cancer Patients.
Peralba JM; DeGraffenried L; Friedrichs W; Fulcher L; Grünwald V; Weiss G; Hidalgo M
Clin Cancer Res; 2003 Aug; 9(8):2887-92. PubMed ID: 12912932
[TBL] [Abstract][Full Text] [Related]
44. Inhibition of the mammalian target of rapamycin (mTOR) by rapamycin increases chemosensitivity of CaSki cells to paclitaxel.
Faried LS; Faried A; Kanuma T; Nakazato T; Tamura T; Kuwano H; Minegishi T
Eur J Cancer; 2006 May; 42(7):934-47. PubMed ID: 16540312
[TBL] [Abstract][Full Text] [Related]
45. Antagonism of the mammalian target of rapamycin selectively mediates metabolic effects of epidermal growth factor receptor inhibition and protects human malignant glioma cells from hypoxia-induced cell death.
Ronellenfitsch MW; Brucker DP; Burger MC; Wolking S; Tritschler F; Rieger J; Wick W; Weller M; Steinbach JP
Brain; 2009 Jun; 132(Pt 6):1509-22. PubMed ID: 19416948
[TBL] [Abstract][Full Text] [Related]
46. Effects of selective somatostatin analogs and cortistatin on cell viability in cultured human non-functioning pituitary adenomas.
Padova H; Rubinfeld H; Hadani M; Cohen ZR; Nass D; Taylor JE; Culler MD; Shimon I
Mol Cell Endocrinol; 2008 May; 286(1-2):214-8. PubMed ID: 18276067
[TBL] [Abstract][Full Text] [Related]
47. Involvement of extracellular signal-related kinase signaling in esculetin induced G1 arrest of human leukemia U937 cells.
Lee SH; Park C; Jin CY; Kim GY; Moon SK; Hyun JW; Lee WH; Choi BT; Kwon TK; Yoo YH; Choi YH
Biomed Pharmacother; 2008 Dec; 62(10):723-9. PubMed ID: 18222060
[TBL] [Abstract][Full Text] [Related]
48. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.
Baselga J; Semiglazov V; van Dam P; Manikhas A; Bellet M; Mayordomo J; Campone M; Kubista E; Greil R; Bianchi G; Steinseifer J; Molloy B; Tokaji E; Gardner H; Phillips P; Stumm M; Lane HA; Dixon JM; Jonat W; Rugo HS
J Clin Oncol; 2009 Jun; 27(16):2630-7. PubMed ID: 19380449
[TBL] [Abstract][Full Text] [Related]
49. Rapamycin inhibits proliferation of estrogen-receptor-positive breast cancer cells.
Chang SB; Miron P; Miron A; Iglehart JD
J Surg Res; 2007 Mar; 138(1):37-44. PubMed ID: 17109887
[TBL] [Abstract][Full Text] [Related]
50. Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors.
Kenerson HL; Aicher LD; True LD; Yeung RS
Cancer Res; 2002 Oct; 62(20):5645-50. PubMed ID: 12384518
[TBL] [Abstract][Full Text] [Related]
51. Morphoproteomic and molecular concomitants of an overexpressed and activated mTOR pathway in renal cell carcinomas.
Lin F; Zhang PL; Yang XJ; Prichard JW; Lun M; Brown RE
Ann Clin Lab Sci; 2006; 36(3):283-93. PubMed ID: 16951269
[TBL] [Abstract][Full Text] [Related]
52. Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinic.
Huang S; Houghton PJ
Curr Opin Investig Drugs; 2002 Feb; 3(2):295-304. PubMed ID: 12020063
[TBL] [Abstract][Full Text] [Related]
53. Targeted therapy of human osteosarcoma with 17AAG or rapamycin: characterization of induced apoptosis and inhibition of mTOR and Akt/MAPK/Wnt pathways.
Gazitt Y; Kolaparthi V; Moncada K; Thomas C; Freeman J
Int J Oncol; 2009 Feb; 34(2):551-61. PubMed ID: 19148492
[TBL] [Abstract][Full Text] [Related]
54. Rapamycin selectively inhibits expression of an inducible keratin (K6a) in human keratinocytes and improves symptoms in pachyonychia congenita patients.
Hickerson RP; Leake D; Pho LN; Leachman SA; Kaspar RL
J Dermatol Sci; 2009 Nov; 56(2):82-8. PubMed ID: 19699613
[TBL] [Abstract][Full Text] [Related]
55. Morphoproteomic and pharmacoproteomic rationale for mTOR effectors as therapeutic targets in head and neck squamous cell carcinoma.
Brown RE; Zhang PL; Lun M; Zhu S; Pellitteri PK; Riefkohl W; Law A; Wood GC; Kennedy TL
Ann Clin Lab Sci; 2006; 36(3):273-82. PubMed ID: 16951268
[TBL] [Abstract][Full Text] [Related]
56. Differential effects of rapamycin on mammalian target of rapamycin signaling functions in mammalian cells.
Edinger AL; Linardic CM; Chiang GG; Thompson CB; Abraham RT
Cancer Res; 2003 Dec; 63(23):8451-60. PubMed ID: 14679009
[TBL] [Abstract][Full Text] [Related]
57. Regulation of cell growth and cyclin D1 expression by the constitutively active FRAP-p70s6K pathway in human pancreatic cancer cells.
Grewe M; Gansauge F; Schmid RM; Adler G; Seufferlein T
Cancer Res; 1999 Aug; 59(15):3581-7. PubMed ID: 10446965
[TBL] [Abstract][Full Text] [Related]
58. Mechanism of apicidin-induced cell cycle arrest and apoptosis in Ishikawa human endometrial cancer cells.
Ahn MY; Lee J; Na YJ; Choi WS; Lee BM; Kang KW; Kim HS
Chem Biol Interact; 2009 May; 179(2-3):169-77. PubMed ID: 19070610
[TBL] [Abstract][Full Text] [Related]
59. Inhibition of the mammalian target of rapamycin and the induction of cell cycle arrest in mantle cell lymphoma cells.
Hipp S; Ringshausen I; Oelsner M; Bogner C; Peschel C; Decker T
Haematologica; 2005 Oct; 90(10):1433-4. PubMed ID: 16219581
[TBL] [Abstract][Full Text] [Related]
60. Phorbol 12-myristate 13-acetate and serum synergize to promote rapamycin-insensitive cell proliferation via protein kinase C-eta.
Martin PM; Aeder SE; Chrestensen CA; Sturgill TW; Hussaini IM
Oncogene; 2007 Jan; 26(3):407-14. PubMed ID: 16832347
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
